Rigel Pharmaceuticals, Inc. (RIGL) on Monday provided a business update, including preliminary total revenue and TAVALISSE (fostamatinib disodium hexahydrate) bottles sold for the fourth quarter, Fast Track designation granted for warm autoimmune hemolytic anemia (wAIHA), and the company's COVID-19 program.
from RTT - Earnings https://ift.tt/39kMbGf
via IFTTT
No comments:
Post a Comment